2. Academic Validation
  3. Development and validation of the Normalized Organoid Growth Rate (NOGR) metric in brightfield imaging-based assays

Development and validation of the Normalized Organoid Growth Rate (NOGR) metric in brightfield imaging-based assays

  • Commun Biol. 2024 Dec 3;7(1):1612. doi: 10.1038/s42003-024-07329-5.
Christophe Deben 1,  Edgar Cardenas De La Hoz 2,  Felicia Rodrigues Fortes 3,  Maxim Le Compte 3,  Sofie Seghers 3,  Steve Vanlanduit 2,  Hendrik Vercammen 4 5,  Bert Van Den Bogert 4 5,  Nelson Dusetti 6,  Abraham Lin 3 7,  Geert Roeyen 3 8,  Marc Peeters 3,  Hans Prenen 3 9,  Filip Lardon 3,  Evelien Smits 3 10
Affiliations

Affiliations

  • 1 Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium. christophe.deben@uantwerpen.be.
  • 2 Industrial Vision Lab, University of Antwerp, Wilrijk, Belgium.
  • 3 Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium.
  • 4 Antwerp Research Group for Ocular Science (ARGOS), Translational Neurosciences, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium.
  • 5 Department of Ophthalmology, Antwerp University Hospital, Edegem, Belgium.
  • 6 Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Aix-Marseille Université and Institut Paoli-Calmettes, 13288, Marseille, France.
  • 7 Plasma Lab for Applications in Sustainability and Medicine ANTwerp (PLASMANT), University of Antwerp, Wilrijk, Belgium.
  • 8 Department of Hepatobiliary Transplantation and Endocrine Surgery, University Hospital Antwerp (UZA), Edegem, Belgium.
  • 9 Department of Oncology, Multidisciplinary Oncological Center Antwerp, Antwerp University Hospital, Edegem, Belgium.
  • 10 Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium.
PMID: 39627437 DOI: 10.1038/s42003-024-07329-5
Abstract

This study focuses on refining growth-rate-based drug response metrics for patient-derived tumor Organoid screening using brightfield live-cell imaging. Traditional metrics like Normalized Growth Rate Inhibition (GR) and Normalized Drug Response (NDR) have been used to assess Organoid responses to Anticancer treatments but face limitations in accurately quantifying cytostatic and cytotoxic effects across varying growth rates. Here, we introduce the Normalized Organoid Growth Rate (NOGR) metric, specifically developed for brightfield imaging-based assays. A label-free image analysis model was applied to segment organoids precisely, track their growth rates over time, and classify viable and dead organoids. Testing eleven phenotypically distinct pancreatic cancer Organoid models with five chemotherapeutics demonstrates that the NOGR metric more effectively captures cytostatic and cytotoxic drug effects compared to existing methods. This approach enhances the biological relevance of drug sensitivity assessments on organoids and offers a valuable tool for advancing personalized Cancer treatment strategies.

Figures
Products